Inovio Pharmaceuticals, Inc.
Common Stock · USD · NASDAQ
Price
$1.33
Cap
—
Earnings
—
30d Trend
+13.7%
91% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 26×Macro 0.99 (−1%)=26
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate Inovio Pharmaceuticals, Inc. at 26/100 — a VERY WEAK reading on the Brain47 Signal. The strongest factor is technical at 45/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+16.1%
3 MONTHS
-28.2%
12 MONTHS
-39.0%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Technical (45) and Quality (35) are the primary strengths. I note that momentum is the weakest area at 9/100 — this warrants monitoring. Historical volatility is elevated at 91%. I classify this as a speculative position — elevated volatility at 91% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.